Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeyu Xie

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Sensors (Basel, Switzerland)|January 27, 2021
Intuitionistic Fuzzy C-Means Algorithm Based on Membership Information Transfer-Ring and Similarity MeasurementHaipeng Chen, Zeyu Xie, Yongping Huang, et al.
Medicine|December 1, 2022
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysisSensen Yang, Weishang Deng, Zeyu Xie, et al.
Medicine|October 6, 2023
CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessmentHangye Gu, Yaqing Chen, Zeyu Xie, et al.
Journal of Diabetes and Its Complications|September 14, 2025
A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in ChinaZeyu Xie, Zhuoru Liang, Guimei Zheng, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2024
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective studyJia Hu, MengTing Li, ZeYu Xie, et al.
Therapeutics and Clinical Risk Management|September 6, 2022
A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular DiseaseZeyu Xie, Jinjian Li, Sensen Yang, et al.
The Journal of Organic Chemistry|March 15, 2022
Cobalt-Catalyzed Regioselective <i>para</i>-Amination of Azobenzenes via Nucleophilic Aromatic Substitution of HydrogenYigao Tao, Rong Hu, Zeyu Xie, et al.
Obesity (Silver Spring, Md.)|November 20, 2025
Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World StudyZeyu Xie, Bin Gan, Weiling Cao, et al.
Shanghai Kou Qiang Yi Xue = Shanghai Journal of Stomatology|October 29, 2025
[The effects of polycaprolactone/gelatin electrospun membranes on MC3T3-E1 osteogenic properties]Yanyin Lin, Zeyu Xie, Yingzhen Lai, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|August 18, 2025
Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic ReviewZeyu Xie, Zhuoru Liang, Yilin Xie, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Sensors (Basel, Switzerland)|January 27, 2021
Intuitionistic Fuzzy C-Means Algorithm Based on Membership Information Transfer-Ring and Similarity MeasurementHaipeng Chen, Zeyu Xie, Yongping Huang, et al.
Medicine|December 1, 2022
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysisSensen Yang, Weishang Deng, Zeyu Xie, et al.
Medicine|October 6, 2023
CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessmentHangye Gu, Yaqing Chen, Zeyu Xie, et al.
Journal of Diabetes and Its Complications|September 14, 2025
A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in ChinaZeyu Xie, Zhuoru Liang, Guimei Zheng, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2024
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective studyJia Hu, MengTing Li, ZeYu Xie, et al.
Therapeutics and Clinical Risk Management|September 6, 2022
A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular DiseaseZeyu Xie, Jinjian Li, Sensen Yang, et al.
The Journal of Organic Chemistry|March 15, 2022
Cobalt-Catalyzed Regioselective <i>para</i>-Amination of Azobenzenes via Nucleophilic Aromatic Substitution of HydrogenYigao Tao, Rong Hu, Zeyu Xie, et al.
Obesity (Silver Spring, Md.)|November 20, 2025
Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World StudyZeyu Xie, Bin Gan, Weiling Cao, et al.
Shanghai Kou Qiang Yi Xue = Shanghai Journal of Stomatology|October 29, 2025
[The effects of polycaprolactone/gelatin electrospun membranes on MC3T3-E1 osteogenic properties]Yanyin Lin, Zeyu Xie, Yingzhen Lai, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|August 18, 2025
Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic ReviewZeyu Xie, Zhuoru Liang, Yilin Xie, et al.
Pageof 4